Gregory Dodell, MD
Endocrinology, Diabetes & Metabolism · New York City, NYNPI 1053622449
Payments from drug & device makers
Across 906 payments — averaging $37.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$10K
- AbbVie$6K
- Lilly USA, LLC$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- Amgen$1K
- plus $11K from 54 others
What the payments were for
- Consulting fees$7,91023%
- Speaking & faculty fees$3,85011%
- Travel & lodging$2781%
- Food & beverage$21,66264%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,712 in reported general payments places this provider in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $205,877 |
| MounjaroTirzepatide | 121 | $183,254 |
| JardianceEmpagliflozin | 123 | $156,880 |
| FarxigaDapagliflozin Propanediol | 67 | $91,721 |
| TrulicityDulaglutide | 45 | $83,125 |
| JanuviaSitagliptin Phosphate | 43 | $56,631 |
| JanumetSitagliptin Phos/Metformin Hcl | 48 | $56,112 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $50,303 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $35,119 |
| Bydureon BciseExenatide Microspheres | 22 | $33,451 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 31 | $31,697 |
| ProliaDenosumab | 15 | $26,680 |
| RybelsusSemaglutide | 18 | $25,711 |
| SynthroidLevothyroxine Sodium | 249 | $24,435 |
| TradjentaLinagliptin | 18 | $21,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $2,041 | $270,817178 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,597 | $235,302175 claims |
| Boehringer IngelheimJardiance, Tradjenta | $483 | $177,912141 claims |
| MerckJanuvia, Janumet, Janumet Xr | $224 | $144,440122 claims |
| AstraZenecaFarxiga | $1,990 | $91,72167 claims |
| AmgenProlia | $1,031 | $26,68015 claims |
| AbbVieSynthroid, Armour Thyroid | $5,951 | $25,793268 claims |
| PfizerEliquis | $344 | $15,18813 claims |
| IBSA Pharma Inc.Tirosint | $380 | $4,27914 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $183 | $4,253400 claims |
| Sanofi-aventis U.S. LLCLantus | $10,212 | $1,77414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York City
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
- Robert SilverBrooklyn$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.